Eton Pharmaceuticals CEO Sean Brynjelsen Sells Shares

What Happened

• Sean Brynjelsen, President & CEO and director of Eton Pharmaceuticals (ETON), sold a total of 100,000 shares in open-market dispositions on Aug 19–20, 2026, for aggregate proceeds of approximately $6,087,773.
• Transaction breakdown:
  • Aug 19, 2026: 8,978 shares at a weighted average $62.65 — $562,472 (F1/F2)
  • Aug 20, 2026: 47,307 shares at a weighted average $60.17 — $2,846,462 (F3)
  • Aug 20, 2026: 36,373 shares at a weighted average $61.11 — $2,222,754 (F4)
  • Aug 20, 2026: 7,342 shares at a weighted average $62.12 — $456,085 (F5)
• These were sales (disposals), not purchases or option exercises.

Key Details

• Dates: Aug 19, 2026 (one tranche) and Aug 20, 2026 (three tranches).
• Prices: weighted-average prices shown above; footnotes indicate the shares were sold in multiple trades at price ranges:
  • F1: $62.50–$63.41 (applies to the Aug 19 tranche)
  • F3: $59.59–$60.59
  • F4: $60.61–$61.61
  • F5: $61.63–$62.52
  • F2: Reporting person will provide per-price trade counts on request.
• Shares owned after the transaction: not specified in the provided excerpt of the filing; see the full Form 4 for post-transaction holdings.
• Filing timeliness: Report filed Aug 20, 2026 for transactions on Aug 19–20 — appears timely under Form 4 rules.
• No 10b5-1 plan, tax withholding, or other alternative disposition method is referenced in the supplied footnotes.

Context

• These are open-market sales by the CEO. Sales provide liquidity to the insider but, by themselves, do not prove a change in company outlook. Purchases generally carry more direct bullish signal for investors.
• If you want precise per-trade details (how many shares sold at each exact price within the ranges), F2 notes the reporting person will provide that information upon request to the SEC, the issuer, or a security holder.